O	0	10	Randomized
O	11	16	trial
O	17	19	of
B-intervention	20	29	denosumab
O	30	32	in
O	33	41	patients
O	42	51	receiving
O	52	60	adjuvant
O	61	70	aromatase
O	71	81	inhibitors
O	82	85	for
O	86	99	nonmetastatic
O	100	106	breast
O	107	113	cancer
O	113	114	.

O	115	123	Adjuvant
O	124	133	aromatase
O	134	143	inhibitor
O	144	151	therapy
O	152	154	is
O	155	159	well
O	160	171	established
O	172	174	in
O	175	189	postmenopausal
O	190	195	women
O	196	200	with
O	201	208	hormone
O	209	217	receptor
O	217	218	-
O	218	226	positive
O	227	233	breast
O	234	240	cancer
O	240	241	,
O	242	245	but
O	246	250	such
O	251	258	therapy
O	259	261	is
O	262	273	complicated
O	274	276	by
O	277	288	accelerated
O	289	293	bone
O	294	298	loss
O	299	302	and
O	303	312	increased
O	313	321	fracture
O	322	326	risk
O	326	327	.

O	328	330	We
O	331	343	investigated
O	344	347	the
O	348	355	ability
O	356	358	of
O	359	368	denosumab
O	368	369	,
O	370	371	a
O	372	377	fully
O	378	383	human
O	384	394	monoclonal
O	395	403	antibody
O	404	411	against
O	412	420	receptor
O	421	430	activator
O	431	433	of
O	434	441	nuclear
O	442	448	factor
O	448	449	-
O	449	455	kappaB
O	456	462	ligand
O	462	463	,
O	464	466	to
O	467	474	protect
O	475	482	against
O	483	492	aromatase
O	493	502	inhibitor
O	502	503	-
O	503	510	induced
O	511	515	bone
O	516	520	loss
O	520	521	.

O	522	530	Eligible
B-eligibility	531	536	women
I-eligibility	537	541	with
I-eligibility	542	549	hormone
I-eligibility	550	558	receptor
I-eligibility	558	559	-
I-eligibility	559	567	positive
I-eligibility	568	581	nonmetastatic
I-eligibility	582	588	breast
I-eligibility	589	595	cancer
I-eligibility	596	603	treated
I-eligibility	604	608	with
I-eligibility	609	617	adjuvant
I-eligibility	618	627	aromatase
I-eligibility	628	637	inhibitor
I-eligibility	638	645	therapy
O	646	650	were
O	651	661	stratified
O	662	664	by
O	665	673	duration
O	674	676	of
O	677	686	aromatase
O	687	696	inhibitor
O	697	704	therapy
O	705	706	(
O	706	707	<
O	708	710	or
O	711	712	=
O	713	714	6
O	715	716	v
O	717	718	>
O	719	720	6
O	721	727	months
O	727	728	)
O	728	729	,
O	730	738	received
O	739	751	supplemental
O	752	759	calcium
O	760	763	and
O	764	771	vitamin
O	772	773	D
O	773	774	,
O	775	778	and
O	779	783	were
O	784	792	randomly
O	793	801	assigned
O	802	804	to
O	805	812	receive
B-control	813	820	placebo
O	821	822	(
O	822	823	n
O	824	825	=
B-control-participants	826	829	125
O	829	830	)
O	831	833	or
O	834	846	subcutaneous
O	847	856	denosumab
O	857	859	60
O	860	862	mg
O	863	864	(
O	864	865	n
O	866	867	=
B-intervention-participants	868	871	127
O	871	872	)
O	873	878	every
O	879	880	6
O	881	887	months
O	887	888	.

O	889	891	At
O	892	902	enrollment
O	902	903	,
O	904	907	all
O	908	916	patients
O	917	921	were
O	922	930	required
O	931	933	to
O	934	938	have
O	939	947	evidence
O	948	950	of
O	951	954	low
O	955	959	bone
O	960	964	mass
O	964	965	,
O	966	975	excluding
O	976	988	osteoporosis
O	988	989	.

O	990	993	The
O	994	1001	primary
O	1002	1005	end
O	1006	1011	point
O	1012	1015	was
B-outcome-Measure	1016	1026	percentage
I-outcome-Measure	1027	1033	change
I-outcome-Measure	1034	1038	from
I-outcome-Measure	1039	1047	baseline
I-outcome-Measure	1048	1050	at
I-outcome-Measure	1051	1056	month
I-outcome-Measure	1057	1059	12
I-outcome-Measure	1060	1062	in
I-outcome-Measure	1063	1069	lumbar
I-outcome-Measure	1070	1075	spine
I-outcome-Measure	1076	1080	bone
I-outcome-Measure	1081	1088	mineral
I-outcome-Measure	1089	1096	density
I-outcome-Measure	1097	1098	(
I-outcome-Measure	1098	1101	BMD
I-outcome-Measure	1101	1102	)
O	1102	1103	.

B-outcome	1104	1106	At
I-outcome	1107	1109	12
I-outcome	1110	1113	and
I-outcome	1114	1116	24
I-outcome	1117	1123	months
O	1123	1124	,
B-outcome	1125	1131	lumbar
I-outcome	1132	1137	spine
I-outcome	1138	1141	BMD
O	1142	1151	increased
O	1152	1154	by
O	1155	1156	5
O	1156	1157	.
O	1157	1158	5
O	1158	1159	%
O	1160	1163	and
O	1164	1165	7
O	1165	1166	.
O	1166	1167	6
O	1167	1168	%
O	1168	1169	,
O	1170	1182	respectively
O	1182	1183	,
O	1184	1186	in
O	1187	1190	the
O	1191	1200	denosumab
O	1201	1206	group
O	1207	1213	versus
O	1214	1221	placebo
O	1222	1223	(
O	1223	1224	P
O	1225	1226	<
O	1227	1228	.
O	1228	1232	0001
O	1233	1235	at
O	1236	1240	both
O	1241	1245	time
O	1246	1252	points
O	1252	1253	)
O	1253	1254	.

O	1255	1264	Increases
O	1265	1269	were
O	1270	1278	observed
O	1279	1281	as
O	1282	1287	early
O	1288	1290	as
O	1291	1292	1
O	1293	1298	month
O	1299	1302	and
O	1303	1307	were
O	1308	1311	not
O	1312	1322	influenced
O	1323	1325	by
O	1326	1334	duration
O	1335	1337	of
O	1338	1347	aromatase
O	1348	1357	inhibitor
O	1358	1365	therapy
O	1365	1366	.

O	1367	1376	Increases
O	1377	1379	in
B-outcome	1380	1383	BMD
O	1384	1388	were
O	1389	1393	also
O	1394	1402	observed
B-outcome	1403	1405	at
I-outcome	1406	1409	the
I-outcome	1410	1415	total
I-outcome	1416	1419	hip
I-outcome	1419	1420	,
I-outcome	1421	1426	total
I-outcome	1427	1431	body
I-outcome	1431	1432	,
I-outcome	1433	1440	femoral
I-outcome	1441	1445	neck
I-outcome	1445	1446	,
I-outcome	1447	1450	and
I-outcome	1451	1454	the
I-outcome	1455	1468	predominantly
I-outcome	1469	1477	cortical
I-outcome	1478	1481	one
I-outcome	1481	1482	-
I-outcome	1482	1487	third
I-outcome	1488	1494	radius
O	1494	1495	.

B-outcome	1496	1500	Bone
I-outcome	1501	1509	turnover
I-outcome	1510	1517	markers
O	1518	1527	decreased
O	1528	1532	with
O	1533	1542	denosumab
O	1543	1552	treatment
O	1552	1553	.

O	1554	1561	Overall
B-outcome	1562	1571	incidence
I-outcome	1572	1574	of
I-outcome	1575	1584	treatment
I-outcome	1584	1585	-
I-outcome	1585	1593	emergent
I-outcome	1594	1601	adverse
I-outcome	1602	1608	events
I-outcome	1609	1610	(
I-outcome	1610	1613	AEs
I-outcome	1613	1614	)
O	1615	1618	was
O	1619	1626	similar
O	1627	1634	between
O	1635	1644	treatment
O	1645	1651	groups
O	1651	1652	.

O	1653	1655	In
O	1656	1661	women
O	1662	1666	with
O	1667	1680	nonmetastatic
O	1681	1687	breast
O	1688	1694	cancer
O	1695	1698	and
O	1699	1702	low
O	1703	1707	bone
O	1708	1712	mass
O	1713	1716	who
O	1717	1721	were
O	1722	1731	receiving
O	1732	1740	adjuvant
O	1741	1750	aromatase
O	1751	1760	inhibitor
O	1761	1768	therapy
O	1768	1769	,
O	1770	1775	twice
O	1775	1776	-
O	1776	1782	yearly
O	1783	1797	administration
O	1798	1800	of
O	1801	1810	denosumab
O	1811	1814	led
O	1815	1817	to
O	1818	1829	significant
O	1830	1839	increases
O	1840	1842	in
O	1843	1846	BMD
O	1847	1851	over
O	1852	1854	24
O	1855	1861	months
O	1862	1864	at
O	1865	1875	trabecular
O	1876	1879	and
O	1880	1888	cortical
O	1889	1893	bone
O	1893	1894	,
O	1895	1899	with
O	1900	1907	overall
O	1908	1910	AE
O	1911	1916	rates
O	1917	1924	similar
O	1925	1927	to
O	1928	1933	those
O	1934	1936	of
O	1937	1944	placebo
O	1944	1945	.
